Alista female sexual dysfunction program
This article was originally published in Pharmaceutical Approvals Monthly
Vivus initiates Phase III trial of its topical alprostadil Alista for treatment of female sexual arousal disorder, the firm announces Sept. 7. Alprostadil, a synthetic prostaglandin, is the same active ingredient found in the company's male erectile dysfunction product Muse. Vivus expects two to four trials in 1,500-2,000 patients will support the Alista NDA, which will be submitted in late 2006 or in 2007 (1Pharmaceutical Approvals Monthly July 1, 2004, p. 24). The firm also has a testosterone spray slated to enter Phase III in 2005...
You may also be interested in...
Procter & Gamble’s testosterone patch Intrinsa could be approved for female sexual dysfunction by January.
Procter & Gamble’s Intrinsa could be the first treatment for female sexual dysfunction to reach the market, with potential approval as early as 2005.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.